<?xml version="1.0" encoding="UTF-8"?>
<p>Although a range of studies have shown contradictory findings on the impact of CMV on immune responses, with some demonstrating a negative effect (
 <xref rid="bib59" ref-type="bibr">Trzonkowski et al., 2003</xref>; 
 <xref rid="bib10" ref-type="bibr">Derhovanessian et al., 2013</xref>; 
 <xref rid="bib60" ref-type="bibr">Turner et al., 2014</xref>; 
 <xref rid="bib15" ref-type="bibr">Frasca et al., 2015</xref>; 
 <xref rid="bib66" ref-type="bibr">Wagner et al., 2018</xref>), some a positive effect (
 <xref rid="bib37" ref-type="bibr">Miles et al., 2008</xref>; 
 <xref rid="bib22" ref-type="bibr">Holder et al., 2010</xref>; 
 <xref rid="bib67" ref-type="bibr">Wald et al., 2013</xref>; 
 <xref rid="bib16" ref-type="bibr">Furman et al., 2015</xref>), and others no effect (
 <xref rid="bib9" ref-type="bibr">den Elzen et al., 2011</xref>; 
 <xref rid="bib41" ref-type="bibr">Oâ€™Connor et al., 2014</xref>), it is likely that a combination of factors contributes to these differing results. First, the impact of CMV on heterologous immune responses may differ between primary and memory responses. The majority of studies focused on boosting memory responses, while we examined responses to the neoantigen Ebola glycoprotein (GP) in naive individuals.
</p>
